Innate Pharma SA Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan Dickinson
- Full Time Employees
- 163
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 117, Avenue de Luminy Marseille PA France 13009
- IPO Date
- Nov 1, 2006
- Website
- innate-pharma.com
- Similar Companies
- Business
- Innate Pharma SA, a clinical-stage biotechnology company, develops immunotherapies that harness the innate immune system to treat cancer patients through antibody drug conjugates, monoclonal antibodies, and multi-specific NK cell engagers via its proprietary ANKET platform. Its lead pipeline candidates include IPH4502, a Nectin-4-targeted ADC for solid tumors; lacutamab, an anti-KIR3DL2 monoclonal antibody for advanced cutaneous T-cell lymphomas and peripheral T-cell lymphomas; and monalizumab, an anti-NKG2A antibody partnered with AstraZeneca for non-small cell lung cancer, with additional assets such as IPH5201 (anti-CD39, partnered with AstraZeneca), IPH5301 (anti-CD73), and the BCMA-targeted ANKET program with Sanofi for autoimmune indications. The company operates primarily in Europe and the United States, serving oncology patients with high unmet needs through collaborations with biopharmaceutical leaders including AstraZeneca, Sanofi, and research institutions. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma lists on Euronext Paris and Nasdaq. Recent developments include a €15 million equity investment from Sanofi in April 2025 amid ongoing BCMA ANKET partnership; FDA clearance for the TELLOMAK-3 trial of lacutamab; prioritization of IPH4502, lacutamab, and monalizumab with approximately 30% staffing reductions for resource focus; enrollment completion in AstraZeneca's Phase 3 PACIFIC-9 monalizumab trial, with data expected in second-half 2026; and advancement of preclinical ADCs leveraging innovative targets.
Company News
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Target Price of $6.67
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
Innate Pharma Announces Conference Call and Webcast
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)